How EAC Works
Electrochemically activated chemotherapy (EAC) works because it is sourcing the body's own enzymatic mechanism, not machinery, at the chemical modification level (figure 1).
Figure 1. Schematic overlap between enzymatic P450 bioactivation and electrochemical activation of (s)ubstrate molecules. Original Source: Boudreau J. (2012). Electrochemical Generation of Toxicants and their Application as Chemotherapeutics. University of Guelph. Page no: 8.
What is bioactivation?
Bioactivation is the naturally occurring metabolic process that makes a molecule more reactive. Bioactivation is used in the body for steroid synthesis; food and drug metabolism; as well as playing a preparatory role in the detoxification of various molecules.
EAC uses a chemotherapeutic galvanostat/potentiostat (CGP), like The Joey™ from Innovative Potential™, to activate a prodrug molecule in one of two ways:
-
by removing a chaperone or protective functional group; or,
-
by increasing a molecule's general reactivity.
The two (2) main benefits of EAC molecules are:
-
EAC starts with non-toxic precursor compounds and then toxifies (i.e.: activates) them to make them pharmacologically effective; and,
-
To create molecules with:
-
new mechanisms of action; and,
-
lower systemic toxicity; and,
-
lower risk hazard profiles in cases of spills; and,
-
increased transportation safety; and,
-
increased shelf-life; and,
-
decreased sensitivity to storage conditions.
There are some limitations to EAC but the general rule is that:
-
if the precursor molecule can enzymatically bioactivate, then EAC will work when the molecule is activated by a CGP by Innovative Potential™.
You can think of EAC as a type of bioactivation, but instead of it occurring with an enzyme, a patented CGP machine from Innovative Potential™ is doing the activation.
